Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sieglinde Reinisch"'
Autor:
Walter Reinisch, Christian Primas, Gottfried Novacek, Harald Vogelsang, Sieglinde Reinisch, Lukas Baumann, Gertrud Hopf
Publikováno v:
Scandinavian Journal of Gastroenterology. 56:1169-1174
Fecal calprotectin (fCP) has been shown to correlate with endoscopic disease activity in Crohn's disease (CD). The aim of this study was to evaluate its role in predicting early endoscopic recurrence in postoperative CD.Patients who underwent CD-rela
Autor:
Pavol Papay, Wolfgang Miehsler, Harald Vogelsang, Walter Reinisch, Donata Lissner, Gottfried Novacek, Sieglinde Reinisch, Christian Primas, Clemens Dejaco, Susanna Scharrer
Publikováno v:
Inflammatory Bowel Diseases. 27:379-385
Background Despite substantial evidence on the negative effect of active smoking, the impact of passive smoking on the course of Crohn’s disease (CD) remains largely unclear. Our aim was to assess passive smoking as a risk factor for intestinal sur
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract. Achieving clinical and endoscopic remission is the main therapeutic goal.
Autor:
Christian Primas, B Itzlinger-Monshi, M Kienbauer, Gottfried Novacek, Christoph Högenauer, Walter Reinisch, B Rainer, Sieglinde Reinisch, Lili Kazemi-Shirazi, M Geroldinger-Simic, Harald Maier, K Sonneck, C Hartl
Publikováno v:
Zeitschrift für Gastroenterologie.
Autor:
Judith Sautner, Wolfgang Weger, Yvonne Helmy-Bader, Andrea Studnicka-Benke, Christoph Högenauer, Josef Hermann, Antonia Puchner, Herbert Juch, Hans Peter Gröchenig, Clemens Dejaco, Robert Koch, Rudolf Puchner, Sieglinde Reinisch
Publikováno v:
Wiener Klinische Wochenschrift
Summary An increasing and early-onset use of immunosuppressives and biologics has become more frequently seen among patients with inflammatory bowel diseases (IBD) and rheumatic disorders. Many women in their childbearing years currently receive such
Autor:
Diane R. Mould, S Lee, Maximilian Kutschera, Christian Primas, Joon Ho Lee, Gottfried Novacek, S Kim, Walter Reinisch, Sieglinde Reinisch
Publikováno v:
Journal of Crohn's and Colitis. 15:S108-S109
Background Treating patients with biologics like infliximab (IFX), may cause the formation of antidrug antibodies (ADA). ADA are associated with faster drug clearance, reduced treatment efficacy and increased risk of infusion-related side effects. Th
Autor:
E Pablik, Benjamin Collet-Fenetrier, Karin Schweiger, Sieglinde Reinisch, Paul Moayyedi, I Alfaro, Laurent Peyrin-Biroulet, Walter Reinisch, Julià Panés
Publikováno v:
Alimentary Pharmacology & Therapeutics. 44:601-611
SummaryBackground The Lennard-Jones criteria are considered the gold standard for diagnosing Crohn's disease (CD) and include the items granuloma, macroscopic discontinuity, transmural inflammation, fibrosis, lymphoid aggregates and discontinuous inf
Publikováno v:
Alimentary pharmacologytherapeutics. 47(4)
Autor:
Alexander Eser, Christian Primas, Diane R. Mould, Sieglinde Reinisch, Gottfried Novacek, Harald Vogelsang, Walter Reinisch
Publikováno v:
Journal of clinical pharmacology. 58(6)
Despite a robust exposure-response relationship of infliximab in inflammatory bowel disease (IBD), attempts to adjust dosing to individually predicted serum concentrations of infliximab (SICs) are lacking. Compared with labor-intensive conventional s
Autor:
M Niapir, Walter Reinisch, Christian Primas, Thomas Waldhör, Lili Kazemi-Shirazi, P Mekhail, N Pedarnig, Gottfried Novacek, Clemens Dejaco, Harald Vogelsang, H Angermann, W. Eigner, Sieglinde Reinisch
Publikováno v:
Journal of Crohn's and Colitis. 13:S165-S165